Cellares Overview
- Year Founded
-
2019
- Status
-
Private
- Employees
-
308
- Latest Deal Type
-
Series D
- Latest Deal Amount
-
$327M
- Investors
-
21
Cellares General Information
Description
Operator of an integrated development and manufacturing organization intended to support cell therapy development. The company offers an automated cell therapy and quality control platform that integrates cell processing, testing, monitoring, and production workflows, enabling biotechnology and pharmaceutical companies to develop, scale, and commercialize cell therapies.
Contact Information
Website
www.cellares.comCorporate Office
- 345 Allerton Avenue
- South San Francisco, CA 94080
- United States
Corporate Office
- 345 Allerton Avenue
- South San Francisco, CA 94080
- United States
Cellares Timeline
Cellares Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Later Stage VC (Series D) | 15-Apr-2026 | $327M | Completed | Generating Revenue | ||
| 4. Mezzanine | 19-Nov-2024 | Completed | Generating Revenue | |||
| 3. Later Stage VC (Series C) | 23-Aug-2023 | Completed | Generating Revenue | |||
| 2. Early Stage VC (Series B) | 05-May-2021 | $82M | $100M | Completed | Generating Revenue | |
| 1. Early Stage VC (Series A) | 01-Aug-2019 | $18M | $18M | Completed | Generating Revenue |
Cellares Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series C-1 | ||||||||
| Series C | ||||||||
| Series B-1 | ||||||||
| Series B | 15,680,430 | $0.000010 | 8% | $5.1 | $5.1 | 1x | $5.1 | 19.76% |
| Series A | 12,203,387 | $0.000010 | 8% | $1.48 | $1.48 | 1x | $1.48 | 15.38% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Cellares Comparisons
Industry
Financing
Details
Cellares Competitors (5)
One of Cellares’s 5 competitors is Ori Biotech, a Venture Capital-Backed company based in London, United Kingdom.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Ori Biotech | Venture Capital-Backed | London, United Kingdom | ||||
| Theragent | Corporation | Los Angeles, CA | ||||
| Creative Biolabs | Corporation | Shirley, NY | ||||
| AGC Biologics | Formerly VC-backed | Bothell, WA | ||||
| KBI BioPharma | Formerly VC-backed | Durham, NC |
Cellares Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Cellares Patents
Cellares Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026220339-A1 | Cell mixtures for validating cell processing systems | Pending | 16-Apr-2025 | ||
| US-20260265815-A1 | Integrated, multi-instrument system for automated bioprocessing | Pending | 06-Mar-2025 | ||
| WO-2026187380-A1 | Integrated, multi-instrument system for automated bioprocessing | Pending | 06-Mar-2025 | ||
| WO-2026146347-A2 | Automated cell processing with integrated sample preparation and analysis system | Pending | 30-Dec-2024 | ||
| WO-2026146347-A3 | Automated cell processing with integrated sample preparation and analysis system | Pending | 30-Dec-2024 | C12M41/48 |
Cellares Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Cellares Investors (21)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| ARK Ventures (US) | Venture Capital | Minority | ||
| Baillie Gifford | Growth/Expansion | Minority | ||
| BlackRock Private Equity Partners | PE/Buyout | Minority | ||
| DC Global Ventures | Venture Capital | Minority | ||
| Duquesne Family Office | Family Office | Minority |
Cellares FAQs
-
When was Cellares founded?
Cellares was founded in 2019.
-
Where is Cellares headquartered?
Cellares is headquartered in South San Francisco, CA.
-
What is the size of Cellares?
Cellares has 308 total employees.
-
What industry is Cellares in?
Cellares’s primary industry is Biotechnology.
-
Is Cellares a private or public company?
Cellares is a Private company.
-
What is Cellares’s current revenue?
The current revenue for Cellares is .
-
How much funding has Cellares raised over time?
Cellares has raised $686M.
-
Who are Cellares’s investors?
ARK Ventures (US), Baillie Gifford, BlackRock Private Equity Partners, DC Global Ventures, and Duquesne Family Office are 5 of 21 investors who have invested in Cellares.
-
Who are Cellares’s competitors?
Ori Biotech, Theragent, Creative Biolabs, AGC Biologics, and KBI BioPharma are competitors of Cellares.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
